We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Scholar Rock Holding Corp
7 own
10 watching
Current Price
$41.54
$-1.06
(-2.49%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
698.68M
52-Week High
46.18500
52-Week Low
6.76000
Average Volume
1.28M
Dividend Yield
--
P/E Ratio
--
Market Capitalization698.68M52-Week High46.1850052-Week Low6.76000Average Volume1.28MDividend Yield--P/E Ratio--What does the Scholar Rock Holding Corp do?
Scholar Rock Holding Corporation is a biopharmaceutical company. The Company is focused on the discovery, development and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its transforming growth factor beta (TGFb) superfamily biology, its novel molecular mechanisms of growth factor activation enabled the Company to develop a proprietary platform for the development of monoclonal antibodies that locally and selectively target the precursor. Its product candidate, apitegromab, is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Apitegromab is being developed as the first muscle-targeted therapy for the treatment of spinal muscular atrophy (SMA). Its other product candidate, SRK-181, a selective inhibitor of the activation of latent TGFb, is being developed for the treatment of cancers.
Read More
How much money does Scholar Rock Holding Corp make?
News & Events about Scholar Rock Holding Corp.
Business Wire
1 year ago
Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced...
Business Wire
1 year ago
Scholar Rock (NASDAQ: SRRK; The Company), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the Company granted inducement equity awards covering an aggregate of 83,125...
Zolmax
1 year ago
Scholar Rock Holding Co. (NASDAQ:SRRK Get Rating) Analysts at Wedbush issued their Q1 2024 earnings per share estimates for shares of Scholar Rock in a research note issued to investors on Tuesday, March 7th. Wedbush analyst D. Nierengarten anticipates that the company will earn ($0.67) per share ...
Business Wire
1 year ago
Scholar Rock (NASDAQ: SRRK; The Company), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the Company granted inducement equity awards covering an aggregate of 285,000...
Ticker Report
2years ago
Scholar Rock Holding Co. (NASDAQ:SRRK Get Rating) major shareholder Public Equities L.P. Invus bought 48,774 shares of the companys stock in a transaction that occurred on Thursday, January 5th. The shares were bought at an average cost of $9.33 per share, for a total transaction of $...
Frequently Asked Questions
Frequently Asked Questions
What is Scholar Rock Holding Corp share price today?
Can Indians buy Scholar Rock Holding Corp shares?
How can I buy Scholar Rock Holding Corp shares from India?
Can Fractional shares of Scholar Rock Holding Corp be purchased?
What are the documents required to start investing in Scholar Rock Holding Corp stocks?
What is today’s traded volume of Scholar Rock Holding Corp?
What is today’s market capitalisation of Scholar Rock Holding Corp?
What is the 52-Week High and Low Range of Scholar Rock Holding Corp?
What percentage is Scholar Rock Holding Corp down from its 52-Week High?
What percentage is Scholar Rock Holding Corp up from its 52-Week Low?
Current Price
$41.54
$-1.06
(-2.49%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.